Patent 7723484 was granted and assigned to APPLIED MOLECULAR EVOLUTION on May, 2010 by the United States Patent and Trademark Office.
The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.